Positive Ph3 Data for Aspergillosis Antifungal Treatment
Phase 3 trial results indicate a new antifungal medication olorofim is as effective as current standard treatments for invasive aspergillosis with fewer side effects.
Category: US Pharmaceuticals
US Pharmaceuticals
Latest
Positive Ph3 Data for Aspergillosis Antifungal Treatment
Phase 3 trial results indicate a new antifungal medication olorofim is as effective as current standard treatments for invasive aspergillosis with fewer side effects.
Read More
CFTR Modulator Use Linked to Lower Anxiety in Children and Parents
New research suggests cystic fibrosis transmembrane conductance regulator (CFTR) modulators may provide mental health benefits for pediatric patients and their caregivers early in treatment.
Read More
FDA Approves Capvaxive Pneumococcal Vaccine for Children 2-17
The USFDA approved an expanded indication for Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to include children and adolescents aged 2 through 17 years, according to Merck.
Read More
FDA Approves Generic Xofluza
The FDA approved the first generic of Xofluza (baloxavir marboxil) tablets, the first single-dose treatment for acute uncomplicated influenza and prophylaxis in patients 5 years of age and older.
Read More
FDA Approves OTC Rextovy for Opioid Overdose
Rextovy, a 4 mg naloxone medication, will be available for purchase without a prescription at retail stores and online.
Read More
ENA Respiratory Secures Two US Patents for COPD Therapy
ENA Respiratory received notices of allowance for two US patents covering its innate immune modulators and their application in preventing COPD exacerbations.
Read More
Unique Attack Method for New Antibiotic
Researchers discovered manikomycin, a soil-derived peptide that attacks bacteria in a unique way to bypass existing antibiotic resistance.
Read More
Maternal RSV Vaccine Cuts Infant Hospitalizations Nearly 70%
Real-world data published in JAMA Network Open confirm the effectiveness of the RSVpreF vaccine in protecting newborns from respiratory syncytial virus.
Read More
Certain Flu Drugs May Reduce Cognitive Decline
Researchers found that sialidase inhibitors—a class of flu drugs including oseltamivir (Tamiflu)—protected against degradation of protective sugar molecules tied to cognitive decline and premature aging in people living with HIV.
Read More
Factors That Influence Parent Decisions on Pediatric COVID-19 Vaccination
Researchers found that five core values—safety, knowledge, trust, humanity, and autonomy—shape how minority parents approach pediatric vaccination.
Read More
Combination CF Drugs Formoterol + Methacholine May Improve Mucus Clearance
Combining formoterol and methacholine significantly improves mucociliary clearance in animal models of cystic fibrosis, compared to using either drug alone.
Read More
Nanoparticles Increase Lung Cancer Drug Delivery 30-fold
Researchers at Adelaide University developed a lipid-polymer vehicle that improves drug bioavailability and reduces systemic toxicity in preclinical models of lung cancer.
Read More
New Data on Childhood Flu Vaccine Efficacy
For every 100 children vaccinated against influenza, between nine and 14 cases are prevented, according to Harvard Medical School data.
Read More
Long-Term Data for Recurrent Respiratory Papillomatosis Therapy
Updated clinical data demonstrates that Papzimeos for adults with Recurrent Respiratory Papillomatosis (RRP) can maintain complete responses for more than four years.
Read More
New Avian Flu Vaccine Shows Promise in Protecting Humans, Cattle
Researchers developed an avian flu vaccine platform that generates immunity in the respiratory tract and bloodstream to combat H5N1.
Read More
Racial, Ethnic Disparities Persist in Asthma Inhaler Use
A study of over 1.1 million American adults with asthma found that Black, Hispanic, and Asian patients use ICS, LABA and LAMA inhalers less frequently than white patients.
Read More
Inhaled Molgramostim Improved Exercise Capacity
Phase 3 clinical trial data shows improvements in walking distance and duration for patients with autoimmune pulmonary alveolar proteinosis treated with inhaled molgramostim.
Read More
Nebulized Treprostinil Preserved IPF Lung Function
Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).
Read More
Inhaled Nitric Oxide Therapy Alx1 Well Tolerated in Ph1 Trial
Phase 1 data for the investigational inhaled nitric oxide therapy Alx1 demonstrated the treatment was well tolerated with no serious side effects in healthy volunteers.
Read More
Nebulized Dual Bronchodilator Aero-007 Improved COPD Lung Function
AERO-007 demonstrated significant lung function improvements over 24 hours in patients with moderate-to-severe COPD.
Read More
Alpha-1 Drug Candidate Superior to Standard Care
Phase 2 data for efdoralprin alfa demonstrate the recombinant protein maintains normal protein levels with less frequent dosing than current standards of care for patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema.
Read More
Tezepelumab Reduced Asthma Attacks
A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.
Read More
Sleep Apnea Pill Reduced Breathing Interruptions
A phase 3 trial found that AD109 (aroxybutynin and atomoxetine) reduced breathing interruptions and improved oxygen levels in patients with obstructive sleep apnea.
Read More
FDA Approves Benralizumab for Hypereosinophilic Syndrome
Benralizumab (Fasenra) is now indicated to reduce the risk of flare ups for adult and pediatric patients with hypereosinophilic syndrome.
Read More